Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed in two different programs: obesity-enobosarm in combination with GLP-1 RA to augment fat loss, to prevent muscle loss, and maintain physical function for higher quality weight loss, and breast cancer-enobosarm plus abemaciclib for the second line treatment of androgen receptor positive, estrogen receptor positive and others. Sabizabulin, a microtubule disruptor, is being developed for the treatment of hospitalized patients with viral-induced ARDS. It also has an FDA-approved commercial product, FC2 Female Condom (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections.